<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160818029414N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-03-21</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>Comparision of the addition of Fentanyl and Sufentanil to Bupivacaine on labor analgesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparision of Fentanyl –Bupivacaine and Sufentanyl –Bupivacaine for Inthrathecal Labour Analgesia in pregnant women.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/23651</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Blocked randomization, Blinding description: The mothers participating in the study after obtaining the informed consent of the spinal anesthesia and explaining the possible side effects of the medication by the anesthetist and the relevant caregiver (clinicians) without mentioning the name
The analgesic group has been shown to be analgesic and the practitioner is also aware of the effects of the medication group. The outcome analyst who is the statistic consultant is also not aware of the medication used.</study_design>
      <phase>N/A</phase>
      <hc_freetext>labor pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: Pregnant mothers were referred to the Mousavi Hospital in the active phase of labor and their first or second term pregnancy. 50 micrograms of fentanyl and 2.5 mg of bupivacaine were injected through the number of 25 spinal needle  to space of L3-L4 or L4-L5 in sitting position. Intervention 2: Intervention group: Intervention group: Intervention group: Pregnant mothers were referred to the Mousavi Hospital in the active phase of labor and their first or second term pregnancy. 5 micrograms of Sufentanyl  and 2.5 mg of bupivacaine were injected through the number of 25 spinal needle  to space of L3-L4 or L4-L5 in sitting position. Intervention 3: Control group: Pregnant mothers who are referred to Mousavi Hospital, who are in the active phase of labor, and their first or second term pregnancy, are examined for the course of labor.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>zohre pishgahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ayatollah Musavi hospital., Gavazang road</address>
        <city>zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4515613113</zip>
        <telephone>+98 24 3313 0000</telephone>
        <email>drz.pishgahi@gmail.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Vahideh Rashtchi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Musavi Hospital,Gavazang Avenue</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4513956183</zip>
        <telephone>+98 24 3313 0000</telephone>
        <email>vrasshtchi@gmail.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant woman with age between 15 to 45 and with gestational age between 38 weeks and more
Negative past medical history
One or two gravid</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patient dissatisfaction
Infection in the site of spinal needle
High intracranial pressure
Coagulation disorders
History of allergy to narcotic drugs or anesthetics
Presence of underlying disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: Pregnant mothers were referred to the Mousavi Hospital in the active phase of labor and their first or second term pregnancy. 50 micrograms of fentanyl and 2.5 mg of bupivacaine were injected through the number of 25 spinal needle  to space of L3-L4 or L4-L5 in sitting position.</i_keyword>
      <i_keyword>Intervention group: Intervention group: Intervention group: Pregnant mothers were referred to the Mousavi Hospital in the active phase of labor and their first or second term pregnancy. 5 micrograms of Sufentanyl  and 2.5 mg of bupivacaine were injected through the number of 25 spinal needle  to space of L3-L4 or L4-L5 in sitting position.</i_keyword>
      <i_keyword>Control group: Pregnant mothers who are referred to Mousavi Hospital, who are in the active phase of labor, and their first or second term pregnancy, are examined for the course of labor.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Labor pain. Timepoint: From the time of analgesia to the end of labor or the end of anesthesia. Method of measurement: Based on the questionnaire completed by the researcher, the time is defined in terms of minutes and pain relief based on the pain ruler.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Baby apgar. Timepoint: One and a five minutes after childbirth. Method of measurement: The neonatal Apgar score is based on five items: heart rate, muscle tone, baby color, respiratory effort, reflexive irritability. Heart rate less than one hundredth of a person is more than 100 points and in the absence of a score of zero. Irregular respiratory rate score is 1 and A good cry is a score of 2, and in the absence of a score of zero. Your loose muscle is zero and if you have some degrees of flexion, the score 1 and the active motions score 2. If there is no reflexive irritation, the score is zero and in the case of change The baby's face will score one and, in the case of a severe cry, score 2. The pale or blue score is zero, the pink body and The blue endings score one and the whole pink score is 2.</sec_outcome>
      <sec_outcome>Patient satisfaction with analgesia. Timepoint: Immediately after childbirth. Method of measurement: A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. It is often used in epidemiologic and clinical research to measure the intensity or frequency of various.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-08-08</approval_date>
        <contact_name>Zanjan univercity of medical sciences</contact_name>
        <contact_address>Azadi Avenue Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
